D&O Ongoing Disclosure Notice

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013
To NZX Limited; and
Name of listed issuer:
Promisia Healthcare Limited
Date this disclosure made:
13-May-22
Date of last disclosure:
N/A
Director or senior manager giving disclosure
Full name(s):
Stuart Bilbrough
Name of listed issuer:
Promisia Healthcare Limited
Name of related body corporate (if applicable):
N/A
Position held in listed issuer:
CEO
Summary of acquisition or disposal of relevant interest (excluding specified derivatives)
Class of affected quoted financial products:
Unpaid ordinary shares under the
Promisia Employee Share Scheme
Nature of the affected relevant interest(s):
Legal and beneficial ownership
For that relevant interest-
Number held in class before acquisition or disposal:
nil
Number held in class after acquisition or disposal:
500,000,000
Current registered holder(s):
Promisia Trustee Limited
Registered holder(s) once transfers are registered:
Promisia Trustee Limited
Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative:
N/A
Class of underlying financial products:
N/A
Details of affected derivative-
The notional value of the derivative (if any) or the notional amount of underlying
financial products (if any):
N/A
A statement as to whether the derivative is cash settled or physically settled:
N/A
Maturity date of the derivative (if any):
N/A
Expiry date of the derivative(if any):
N/A
The price specified in the terms of the derivative (if any):
N/A
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the
underlying financial products:
N/A
For that derivative,-
Parties to the derivative:
N/A
If the director or senior manager is not a party to the derivative, the nature of the
relevant interest in the derivative:
N/A
Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates: 1

Details of transactions requiring disclosure-
Date of transaction:12-May-22
Nature of transaction:
Allocation of shares under Employee
Share Scheme.
Name of any other party or parties to the transaction (if known):None
The consideration, expressed in New Zealand dollars, paid or received for the
acquisition or disposal. If the consideration was not in cash and cannot be readily by
converted into a cash value, describe the consideration:
Granted under the Promisia
Employee Share Scheme. All shares
are unpaid and have an issue price
of $0.001 per share. The issue price
must be paid within three years in
respect of the shares as they vest in
four 125 million tranches,
commencing annually from 9 May
2022.
Number of financial products to which the transaction related: 500,000,000
If the issuer has a financial products trading policy that prohibits directors or senior
managers from trading during any period without written clearance (a closed period)
include the following details—
Whether relevant interests were acquired or disposed of during a closed period:N/A
Whether prior written clearance was provided to allow the acquisition or disposal to
proceed during the closed period:
N/A
Date of the prior written clearance (if any):
N/A
Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products:Nil.
Nature of relevant interest:N/A
For that relevant interest,-
Number held in class:N/A
Current registered holder(s):N/A
For a derivative relevant interest,-
Type of derivative:N/A
Details of derivative,-
The notional value of the derivative (if any) or the notional amount of underlying
financial products (if any):
N/A
A statement as to whether the derivative is cash settled or physically settled:N/A
Maturity date of the derivative (if any):N/A
Expiry date of the derivative (if any):N/A
The price's specified terms (if any):N/A
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the
underlying financial products:
N/A
For that derivative relevant interest,-
Parties to the derivative: N/A
If the director or senior manager is not a party to the derivative, the nature of the
relevant interest in the derivative:
N/A
Certification
I, certify that, to the best of my knowledge and belief, the information contained in this
disclosure is correct and that I am duly authorised to make this disclosure by all
persons for whom it is made.
Signature of director or officer:
Date of signature:
or

Signature of person authorised to sign on behalf of director or officer:
Date of signature:13-May-22
Name and title of authorised person:
Matt Yates